Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOV focus shifts away from bicifadine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

DOV Pharmaceutical is implementing a new strategic direction "in which the company will focus its internal efforts on its Phase I and II clinical and preclinical research programs for the development and discovery of drugs to treat neuropsychiatric disorders," the firm announces Oct. 10. Those programs include the firm's triple reuptake inhibitors and preclinical GABA modulators. While DOV had previously been focused on the late stage trials of the analgesic bicifadine, it appears the company now looks at bicifadine as a prime partnering opportunity. DOV is stopping patient dosing in a Phase III back pain trial "in order to best allocate resources"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel